A 3-Year-Old's Metastatic Cancer Vanished After Two Doses of Experimental Therapy
Key Points:
- A three-year-old boy with chemotherapy-resistant hepatoblastoma, a malignant liver cancer, achieved complete tumor regression after receiving experimental CAR T cell therapy targeting glypican-3 (GPC3).
- The therapy involved genetically engineered T cells designed to enhance longevity and tumor-killing ability by expressing immune proteins interleukin-15 and interleukin-21.
- Following two infusions of the GPC3-CAR treatment, the patient showed no signs of cancer after 12 months, marking a significant breakthrough in treating solid tumors with CAR T cell therapy.
- This case, published in The New England Journal of Medicine, suggests potential for CAR T cell therapy to be a safe and effective treatment for GPC3-positive solid tumors, including liver cancer, which is a leading cause of cancer-related deaths worldwide.
- Further clinical trials, including the ongoing CARE and IMPACT studies, are necessary to evaluate the broader efficacy and safety of this treatment in more patients.